Motoyama M, Imaoka T, Ichihara N, Miyauchi S
Fujii Memorial Research Institute, Otsuka Pharmaceutical Co., Ltd.
Gan To Kagaku Ryoho. 1994 Jul;21(8):1209-14.
We investigated the effects of BOF-A2 on the metastasis of colorectal cancer using artificial (experimental) and spontaneous metastasis of Colon 26 tumor cells. BOF-A2 suppressed pulmonary nodules in the artificial metastasis of Colon 26 tumor cells into the lung, and the T/C (%) was 53.1% at 20 mg/kg or 8.3% at 40 mg/kg. BOF-A2 also suppressed pulmonary nodules in the spontaneous metastasis of Colon 26 tumor cells into the lung, and the T/C (%) was 33.3% at 40 mg/kg in postoperative treatment, 33.3% at 10 mg/kg, or 16.7% at 20 mg/kg in preoperative treatment. These effects were accompanied by the prolongation of survival time at each dose. From these results, BOF-A2 showed antimetastatic activity and survival effect, and may be useful for adjuvant chemotherapy to prevent cancer from metastasis to the lung.
我们使用结肠26肿瘤细胞的人工（实验性）转移和自发性转移，研究了BOF-A2对结直肠癌转移的影响。BOF-A2抑制了结肠26肿瘤细胞人工转移至肺部形成的肺结节，在20mg/kg时T/C（%）为53.1%，在40mg/kg时为8.3%。BOF-A2还抑制了结肠26肿瘤细胞自发性转移至肺部形成的肺结节，术后治疗中40mg/kg时T/C（%）为33.3%，术前治疗中10mg/kg时为33.3%，20mg/kg时为16.7%。这些作用在各剂量下均伴随着生存时间的延长。从这些结果来看，BOF-A2显示出抗转移活性和生存效应，可能对预防癌症转移至肺部的辅助化疗有用。
